GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Artiva Biotherapeutics Inc (NAS:ARTV) » Definitions » Notes Receivable

ARTV (Artiva Biotherapeutics) Notes Receivable : $0.00 Mil (As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Artiva Biotherapeutics Notes Receivable?

Artiva Biotherapeutics's Notes Receivable for the quarter that ended in Dec. 2024 was $0.00 Mil.


Artiva Biotherapeutics Notes Receivable Historical Data

The historical data trend for Artiva Biotherapeutics's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Artiva Biotherapeutics Notes Receivable Chart

Artiva Biotherapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Notes Receivable
Get a 7-Day Free Trial - - - - -

Artiva Biotherapeutics Quarterly Data
Dec19 Dec20 Mar21 Sep21 Dec21 Mar22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Artiva Biotherapeutics Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


Artiva Biotherapeutics Notes Receivable Related Terms

Thank you for viewing the detailed overview of Artiva Biotherapeutics's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Artiva Biotherapeutics Business Description

Traded in Other Exchanges
N/A
Address
5505 Morehouse Drive, Suite 100, San Diego, CA, USA, 92121
Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials.